William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential

Climb Bio Inc. (NASDAQ:CLYM) is one of the best stocks under $3 to invest in. On October 16, William Blair analyst Matt Phipps initiated coverage of Climb Bio with an Outperform rating but no price target. The positive rating is based on the potential of the company’s CD19 antibody, budoprutug, which is currently being developed for various autoimmune indications.

Earlier on October 13, H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Climb Bio with a Buy rating and $9 price target. H.C. Wainwright considers Climb Bio to be a disruptive innovator in the treatment of B-cell-mediated autoimmune diseases.

Selvaraju noted that valuations of comparable companies hint at considerable upside potential for Climb Bio’s shares.

Climb Bio Inc. (NASDAQ:CLYM) is a clinical-stage biotechnology company that develops therapies for immune-mediated diseases.

While we acknowledge the potential of CLYM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.